Pfizer plans to buy Global Blood Therapeutics

The largest New York-based company Pfizer Inc is negotiating the purchase of another pharmaceutical manufacturer Global Blood Therapeutics. According to preliminary data, the deal is valued at $5 billion.

Having received funding from the sale of the COVID-19 vaccine, the American pharmaceutical company Pfizer is now making acquisition decisions that could generate billions in sales by the end of this decade.

In 2019, Global Blood's Oxbryta received approval in the United States for the treatment of patients aged 12 years and older with sickle cell anemia. In December of the same year, the drug was approved for use in children under 12 years of age.

In recent months, there has been a revival in the conclusion of transactions in the biotech sector compared to the beginning of the year. At that time, negative investor sentiment and funding cuts were associated with a lack of major acquisitions and a number of drug failures at the clinical trial stage.